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Phospholipase D2, a distinct phospholipase D isoform with novel
regulatory properties that provokes cytoskeletal reorganization
William C. Colley*, Tsung-Chang Sung†, Richard Roll‡, John Jenco†, Scott M.
Hammond†, Yelena Altshuller†, Dafna Bar-Sagi‡§, Andrew J. Morris†§ and
Michael A. Frohman*†§
Background: Activation of phospholipase D (PLD) is an important but poorly
understood component of receptor-mediated signal transduction responses and
regulated secretion. We recently reported the cloning of the human gene
encoding PLD1; this enzyme has low basal activity and is activated by protein
kinase C and the small GTP-binding proteins, ADP-ribosylation factor (ARF),
Rho, Rac and Cdc42. Biochemical and cell biological studies suggest, however,
that additional and distinct PLD activities exist in cells, so a search was carried
out for novel mammalian genes related to PLD1.
Results: We have cloned the gene for a second PLD family member and
characterized the protein product, which appears to be regulated differently from
PLD1: PLD2 is constitutively active and may be modulated in vivo by inhibition.
Unexpectedly, PLD2 localizes primarily to the plasma membrane, in contrast to
PLD1 which localizes solely to peri-nuclear regions (the endoplasmic reticulum,
Golgi apparatus and late endosomes), where PLD activity has been shown to
promote ARF-mediated coated-vesicle formation. PLD2 provokes cortical
reorganization and undergoes redistribution in serum-stimulated cells,
suggesting that it may have a role in signal-induced cytoskeletal regulation
and/or endocytosis.
Conclusions: PLD2 is a newly identified mammalian PLD isoform with novel
regulatory properties. Our findings suggest that regulated secretion and
morphological reorganization, the two most frequently proposed biological roles
for PLD, are likely to be effected separately by PLD1 and PLD2.
Background 
Activation of phosphatidylcholine-specific phospholipase
D (PLD) correlates with both receptor-mediated signal
transduction responses [1,2] and regulated secretion [3–7].
The effects of inhibiting PLD activity have suggested
that PLD plays an important role in both processes. An
additional line of evidence linking PLD to these processes
is that PLD has been shown to be activated by protein
kinase C a (PKCa) and members of the Rho and ADP-
ribosylation factor (ARF) families of small GTP-binding
proteins; ARF directs key steps in intracellular protein
traffic (as, less directly, do Rho and PKCa) [5,7–9], and
Rho family members effect changes in cell motility and
morphology [10].
Once activated, PLD generates phosphatidic acid (PA).
The mechanism by which PA affects secretion and mor-
phology has not been established, although several interest-
ing hypotheses have been proposed [2,5,11]. In addition,
PA can be metabolized to form lipids, such as diacylglycerol
and lysophosphatidic acid, which have proven roles as
intracellular and intercellular messengers, respectively
(reviewed in [12]). 
A number of different partially purified PLD activities have
been described in recent years. One well-described set of
activities requires phosphatidylinositol 4,5-bisphosphate
(PIP2), is inhibited by oleate, and is activated by PKCa and
the small GTP-binding proteins Rho and ARF (reviewed in
[13]). Individual PLD activities of this type, enriched from
different subcellular fractions, have been reported to be
activated with different efficacies by ARF, Rho and PKC
[14–17]. A distinct, second type of PLD activity has also
been described which requires oleate but not PIP2 [18], and
which is not activated by ARF [19]. At least one of these
activities has been identified with the recent cloning of the
gene encoding human PLD1 [20].
The PLD1 gene encodes a well-described PLD activity
present in numerous tissues and cell lines [20]. PLD1 has
a low basal rate of catalysis that is sharply increased by a
varied set of regulators including PKCa, ARF and RhoA
Addresses: *Program in Genetics, †Department of
Pharmacological Sciences, ‡Department of
Molecular Genetics and Microbiology, and
§Institute for Cell and Developmental Biology,
State University of New York, Stony Brook, New
York 11794-8651, USA.
Correspondence: Michael A. Frohman
E-mail: Michael@pharm.som.sunysb.edu
Received: 20 December 1996
Revised: 3 February 1997
Accepted: 3 February 1997
Published: 18 February 1997
Electronic identifier: 0960-9822-007-00191
Current Biology 1997, 7:191–201
© Current Biology Ltd ISSN 0960-9822
Research Paper 191
family members [20,21]. PLD1 activity requires PIP2 and
is inhibited by oleate. Purified recombinant PLD1 can be
activated independently by members of each of the
known categories of PLD activator (PKCa, ARF and
Rho), underscoring the complex nature of PLD1 activa-
tion and regulation. These properties of PLD1, in combi-
nation with earlier studies on PLD activity, have
prompted us to hypothesize that PLD1 participates both
in regulating secretion, in coordination with ARF and
PKCa, and in propagating signal transduction responses,
such as cytoskeletal reorganization, through interaction
with RhoA family members [6]. 
Nonetheless, in addition to those already mentioned
above, PLD activities with distinct properties that are dif-
ficult to reconcile with the in vitro properties of PLD1
have been reported in association with selected signal
transduction events and with Src- and Ras-mediated onco-
genic transformation [22–26]. In support of the argument
for there being additional mammalian PLD1-related iso-
forms, the available evidence suggests that PLD1-related
enzymes in other species are quite varied in their regula-
tory properties and requirements; the PLD1 homolog in
yeast is active in the absence of PKC and small G proteins
[12,27], and PLD1 homologs and activities in plants do
not require PIP2 [28,29]. Alternatively, regulatory
processes, such as the post-transcriptional or post-transla-
tional modification of PLD1, or the variable presence of
PLD activators or inhibitors, might account for the differ-
ent PLD activities found in mammalian cells. A splice
variant of PLD1 occurs in which a 38 amino-acid exon is
excluded [21], although the regulatory properties of the
two proteins generated by the alternately spliced cDNAs
appear indistinguishable.
To investigate whether distinct PLD enzymes exist, we
searched for novel PLD1-related mammalian genes. We
have identified PLD2, a second mammalian phosphatidyl-
choline-specific PLD. Our results show that PLD2 is reg-
ulated in a very different manner from PLD1, localizes to
a separate region of the cell, and when overexpressed pro-
motes different cellular responses than PLD1. These
findings suggest that PLD1 and PLD2 mediate distinct
cellular processes.
Results and discussion
Cloning of PLD2
To search for PLD1-related genes, the PLD1 cDNA
coding region was used as a probe to screen a mouse
embryonic library at reduced stringency. Approximately
20 cDNA clones encoding an overlapping but incomplete
coding region were isolated, and the remaining sequence
generated by 5′ rapid amplification of cDNA ends
(RACE) [30]. The PLD2 coding region encodes a
932 amino-acid protein (Fig. 1) that exhibits extensive
homology to PLD1 throughout its length, particularly in
regions thought to be required for catalysis [12,20,31].
Less similarity is observed between the amino termini,
which are not required for catalysis in either PLD1 or
PLD2 (T-C.S. and M.A.F., unpublished observations). In
addition, PLD2 does not encode a PLD1-like ‘loop’
region, which is found in PLD1 but not in PLDs from
non-animal species [12,20]. Overall, the human PLD1 and
mouse PLD2 (mPLD2) proteins are 51% identical; by
comparison, the human and mouse PLD1 proteins are
92% identical (W.C.C. and M.A.F., unpublished observa-
tions). Several human short expressed sequence tags
(ESTs) encoding overlapping peptide sequences highly
similar to mPLD2 were entered into Genbank subsequent
to our cloning of mPLD2. Assuming that these ESTs
encode parts of human PLD2, human and mouse PLD2
proteins are about 96% identical over the partial regions
available for comparison (data not shown). All of the ESTs
presently listed in Genbank that show significant homol-
ogy to the cloned PLDs appear to correspond to either
PLD1 or PLD2.
Unexpected PLD2 basal activity in vitro
To begin to investigate whether PLD1 and PLD2 are
functionally redundant, we expressed and purified PLD2
and examined its basal and activated rates of catalysis. We
previously reported that PLD1 could be expressed using
baculovirus and purified [20,21]. PLD2 was similarly
expressed and purified; no proteins other than PLD1 or
PLD2 were detectable in the purified preparations by
either Coomassie blue (data not shown) or silver staining
(Fig. 2a). As reported before, PLD1 has an extremely low
level of basal activity and can be activated by PKCa and
members of the Rho and ARF families; the effects of
these activators on PLD1 are synergistic (Fig. 3a; and see
[21]). In the presence of all three activators, PLD1 activity
is increased about 250-fold over basal levels.
In contrast, PLD2 unexpectedly exhibits a high basal
activity, about 1500-fold greater than that of PLD1 (Fig.
3b). Moreover, addition of the factors that activate PLD1
— PKCa and members of the Rho and ARF families —
do not further increase PLD2 activity, suggesting that
isolated PLD2 is already fully active. Rac1 and Cdc42,
which activate PLD1 [21], also do not further activate
PLD2 (data not shown). The actual catalytic mechanisms
employed by PLD1 and PLD2 appear to be similar; both
require PIP2 as a cofactor and exhibit similar substrate
specificity and requirements for cations (Fig. 3b and data
not shown). Purification of endogenous mPLD2 from
adult tissues using immunoaffinity chromatography has
been achieved, and in vitro analysis of this PLD2 yields
similar results (A.J.M., unpublished observations). This
excludes the possibility that the unexpected regulatory
properties of our recombinant PLD2 derive from an
aberrant composite cDNA produced during the cloning
of mPLD2.
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Our results suggest that PLD2 is active in the default state,
in contrast to PLD1 which is basally inactive. Although we
cannot definitively rule out the possible copurification of a
PLD2 activator, this appears very unlikely for the follow-
ing reasons. First, immunopurification of PLD1 from sf9
cell extracts using the protocol described for PLD2 results
in essentially complete depletion of PLD1 activators,
which have to be added back to restore activity, but
immunopurification of PLD2 does not result in a substan-
tial decrease in PLD2 activity. Second, PLD1 effectors
maximally activate PLD1 only at relatively high concentra-
tions (0.1–1 mM; see [21]), but silver staining of the puri-
fied PLD2 protein indicates that contaminating proteins
are not detectable, and are certainly not present in stoichio-
metric amounts or anything approaching millimolar con-
centrations. Third, PLD2 activity in vitro is not dependent
on GTPgS or phorbol ester (PMA), ruling out the most
obvious types of activator.
PLD2 is highly active in vivo
The assay used to measure PLD activity in vitro is well
characterized and accepted [32], but is not representative
of the physiological cellular environment in several
respects. One possible explanation for the high basal level
of PLD2 activity in vitro might be that it behaves anom-
alously in this assay, which is optimized for studying
PLD1-like activities. To determine whether the high
PLD2 basal activity observed in vitro is indicative of its
behavior in vivo, we examined PLD2 activity in intact
cells. COS-7 cells were transiently transfected with either
PLD1 or PLD2 expression vectors and assayed using the
transphosphatidylation method, which measures PLD’s
unique propensity to convert phosphatidylcholine into
phosphatidylbutanol in the presence of butanol [33]. 
Control transfected COS-7 cells had almost undetectable
PLD activity (Fig. 4a), consistent with our prior observa-
tions for this cell line [20]. Transfection of these cells
with PLD1 did not greatly increase the observed activity,
suggesting that PLD1 is largely inactive under our
culture conditions in the absence of stimulation.
However, substantial activity was observed after trans-
fection with PLD2 (Fig. 4a), demonstrating that the cel-
lular environment in vivo supports spontaneous
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Figure 1
    1 MSLKNEPRVNTSALQKIAAD MSNIIENLDTRELHFEGEEV DYDVSPSDPKIQEVYIPFSA IYNTQGFKEPNIQTYLSGCP IKAQVLEVERFTSTTRVPSI
    1           MTVTQKNLFP YGD---YLNSSQLHMEPDEV DTLREGEDPADRMH--PYLA IYDLQPLKAHPL-VFAPGVP VIAQVVGTERYTSGSKVGTC

  100 NLYTIELTHGEFKWQVKRKF KHFQEFHRELLKYKAFIRIP IPTRRHTFRRQNVREEPREM PSLPRSSENMIREEQFLGRR KQLEDYLTKILKMPMYRNYH
   84 TLYSVRLTHGDFTWTTKKKF RHFQELHRDLQRHKVLMSLL PLARFAVTHSPAREAAAEDI PSLPRGGSEGSARHTAS-KQ KYLENYLNRLLTMSFYRNYH

  200 ATTEFLDISQLSFIHDLGPK GIEGMIMKRSGGHRIPGLNC CGQGRACYRWSKRWLIVKDS FLLYMKPDSGAIAFVLLVDK EFKIKVGKKETETKYGIRID
  183 AMTEFLEVSQLSFIPDLGSK GLEGVIRKRSGGHRVPGFTF CGRDQVCYRWSKRWLVVKDS FLLYMRPETGAISFVQLFDP GFEVQVGKRSTETRYGVRID

  300 NLSRTLILKCNSYRHARWWG GAIEEFIQKHGTNFLKDHRF GSYAAIQENALAKWYVNAKG YFEDVANAMEEANEEIFITD WWLSPEIFLKRPVVEGNRWR
  283 TSHRSLILKCSSYRQARWWG QEITELAQGSGRDFLQLHQH DSYAPPRPGTLARWFVNGAG YFAAVADAILRAQEEIFITD WWLSPEIYLKRPAHSDD-WR

  400 LDCILKRKAQQGVRIFIMLY KEVELALGINSEYTKRTLMR LHPNIKVMRHPDHVSSTVYL WAHHEKLVIIDQSVAFVGGI DLAYGRWDDNEHRLTDVGSV
  381 LDIMLKRKAEEGVRVSILLF KEVELALGINSGYSKRTLML LHPNIKVMRHPDLVT----L WAHHEKLLVVDQVVAFLGGL DLAFGRWDDVQYRLTDLGDP

  500 KRVTSGPSLGSLPPAAMESM ESLRLKDKNEPVQNLPIQKS IDDVDSKLKGIGKPRKFSKF SLYKQLHRHHLHDADSISSI DSTSSYFNHYRSHHNLIHGL
  477 SEPV---------------- -------------------- -------------------- -------------------- --------------------

  600 KPHFKLFHPSSESEQGLTRP HADTGSIRSLQTGVGELHGE TRFWHGKDYCNFVFKDWVQL DKPFADFIDRYSTPRMPWHD IASAVHGKAARDVARHFIQR
  481 -------------------- HLQTPTLGSDPAATPDLSHN QFFWLGKDYSNLITKDWVQL DRPFEDFIDRETTPRMPWRD VGVVVHGVAARDLARHFIQR

  700 WNFTKIMKSKYRSLSYPFLL PKSQTTAHELRYQVPGSVHA NVQLLRSAADWSAGIKYHEE SIHAAYVHVIENSRHYIYIE NQFFISCADDKVVFNKIGDA
  561 WNFTKTTKARYKTPLYPYLL PKSTSTANNLPFMIPGGQCA TVQVLRSVDRWSAGTL--EN SILNAYLHTIRESQHFLYIE NQFFISCSDGRTVLNKVGDE

  800 IAQRILKAHRENQKYRVYVV IPLLPGFEGDISTGGGNALQ AIMHFNYRTMCRGENSILGQ LKAELGNQWINYISFCGLRT HAELEGNLVTELIYVHSKLL
  658 IVDRILKAHEQGQCFRVYLL LPLLPGFEGDISTGGGNSIQ AILHFTYRTLCRGEHSILHR LKAAMGTAWRDYMSICGLRT HGELGGHPISELIYIHSKML

  900 IADDNTVIIGSANINDRSML GKRDSEMAVIVQDTETVPSV MDGKEYQAGRFARGLRLQCF RVVLGYLDDPSEDIQDPVSD KFFKEVWVSTAARNATIYDK
  758 IADDRTVIIGSANINDRSLL GKRDSELAILIKDTEMEPSL MDGVEYQAGRFALSLRGRCF SVILGANTWPDLDLRDPVCD DFFQ-LWQETAENNATIYEQ

 1000 VFRCLPNDEVHNLIQLRDFI NKPVLAKEDPIRAEEELKKI RGFLVQFPFYFLSEESLLPS VGTKEAIVPMEVWT*   1074 
  857 IFRCLPSNATRSLRLSGSMW LWSPWLQSAFLAQ--ELAHI QGHLVHFPLKFLEDESLLPP LGSKEGMIPLEVWT*    932

hPLD1
mPLD2
Comparison of human PLD1 (hPLD1) and mouse PLD2 (mPLD2)
amino-acid sequences. Boxed regions indicate identical amino acids.
The five regions conserved in prokaryote and eukaryote PLD homologs
are highlighted in yellow [12,20], and invariant amino acids required for
catalysis are highlighted in orange (T-C.S. and M.A.F., unpublished
observations). Dashes indicate gaps in the sequence alignment where
there are no residues in PLD2 that correspond to the PLD1 ‘loop’
region. The mPLD2 amino-acid and nucleotide sequences have been
deposited in Genbank under the accession number U87557.
high-level PLD2 activity. Unlike the in vitro experi-
ments (Fig. 3), we cannot determine whether PLD2
activity in the cellular environment is regulated posi-
tively or negatively by unknown cellular factors, though
availability of PIP2 may be rate-limiting for PLD2 activ-
ity in vivo. Nonetheless, taken together with the in vitro
data, our data suggest that PLD2 overexpressed in the
cellular environment is active in the absence of stimula-
tory factors required by PLD1.
One possible explanation for the differential activity of
PLD1 and PLD2 in vivo might be that PLD1 was not
expressed as well as PLD2 after transfection of COS-7
cells. Western blot and immunofluorescence analysis of
the transfected cells indicated that both proteins were
present in moderate amounts (data not shown). However,
such analyses cannot reveal whether the proteins are
functional. The presence of functional PLD1 protein was
demonstrated by using conditions known to trigger PLD1
activation and re-examining the relative amounts of phos-
phatidylbutanol generated in cells producing each PLD
protein. Bypassing ligand stimulation, PLD1 can be acti-
vated in vivo by first using PMA to activate PKC. PMA
addition was accompanied by rapid accumulation of phos-
phatidylbutanol in both PLD1- and PLD2-transfected
cells (Fig. 4b). Compared to cells that were not stimu-
lated with PMA, PLD1-specific catalysis increased
10–15-fold, whereas PLD2-specific catalysis increased
only 2-fold (Fig. 4c).
These results support the findings in vitro by demon-
strating that PLD2 is active in vivo in unstimulated cells,
in contrast to PLD1 which is not basally active. In addi-
tion, the results again suggest that PLD2 is largely
refractory to PKC activation: even the modest two-fold
increase in PLD2 activity on PMA addition could result
from mechanisms other than a direct interaction with
PKC. Although PKCa activates PLD [34,35] and PLD1
[21] in vitro in a non-catalytic (non-ATP-dependent)
manner, PLD activation in vivo is frequently inhibited
when PKC catalytic activity is blocked [34,36], implying
that part of the PKC response in vivo involves phospho-
rylation of a PLD regulator — for example, PKC phos-
phorylation inhibits Ras GTPase-activating protein
(Ras-GAP) which activates Ras, which then activates
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Figure 3
PLD2 exhibits a novel form of regulated activity in vitro. The activities of
(a) PLD1 and (b) PLD2 were determined in the presence of various
combinations of PLD1 activators. Activity was measured using a
headgroup-release assay [20] in the presence of optimal concentrations
of PLD proteins and activators. Dose-response curves with the activators
have previously been performed for PLD1 [20,21]. Dose-response
curves were performed for PLD2 and generated qualitatively similar
results to those shown in this figure. Activation of PLD1 by the small
GTP-binding proteins is dependent on the inclusion of GTPgS in this
assay. Stimulation of PLD1 by PKC is enhanced in this assay by the
presence of phorbol ester (PMA), which activates PKC. However, the
PKC-mediated stimulation is mediated by PKC’s regulatory domain and
is not ATP-dependent. We observed a lack of effect of the small GTP-
binding proteins or PKCa on PLD2 activity, regardless of whether
GTPgS or PMA were present (data not shown). The amounts of PLD
proteins used were adjusted to prevent saturation of the assay. NA
indicates no addition. Similar results were observed in assays of cell
extracts prepared from COS-7 cells transiently transfected with either
PLD1 or PLD2 mammalian expression vectors, except that the PLD1
basal activity was higher (about 15% of the ARF-stimulated PLD1
activity), as a result of limiting quantities of endogenous activators in the
cell lysates (data not shown). As previously reported for PLD1 [20],
PLD2 activity also requires PIP2 (b, last column).
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Figure 2
Recombinant PLD proteins were expressed using baculovirus and
affinity purified using anti-PLD1 and anti-PLD2 peptide antisera. (a)
After purification, PLD1 and PLD2 were the only proteins detectable
by silver staining. Approximately 100 ng of each protein was separated
by electrophoresis; silver staining reveals PLD1 more effectively than
PLD2. (b) Western blot analysis of samples of PLD1 and PLD2, using
the PLD1- and PLD2-specific antisera, confirming the identities of the
bands visible in the silver-stained gel. The approximate positions and
sizes (in kDa) of marker proteins are indicated.
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other small GTP-binding proteins [37]. PIP2 levels and
availability are also altered indirectly after PKC activa-
tion. These results do suggest, however, that PLD2
could account for the numerous reports of agonist-stimu-
lated PKC-independent PLD activity [1]. 
PLD2-specific inhibition in vitro
The striking regulatory differences between PLD1 and
PLD2 are surprising in light of the similarity of the two
proteins (Fig. 1). Identification of a constitutively active
PLD was unexpected: PLD has been studied extensively,
but no such activity has previously been purified. Instead,
only PLD1-like activities have been reported. This
paradox raised the possibility that endogenous PLD2
activity might normally be masked by negative regulators.
According to this model, PLD2 activity would become
transiently derepressed upon ligand stimulation. 
To pursue this hypothesis, we searched in a variety of
mammalian cell lines and tissues for modulators of PLD2
activity. Preliminary studies indicated that several tissue
extracts contained cytosolic factors that inhibited the
activity of purified PLD2 in vitro. Bovine brain was a par-
ticularly rich source of such inhibitory activity and was
used to generate an enriched preparation of the
inhibitor(s). Extracts from brain were subjected to chro-
matographic fractionation, and the fractions were assayed
for the presence of PLD2 inhibitors. 
Analysis of the fractions revealed the presence of several
PLD1 and PLD2 inhibitors, one of which is relatively spe-
cific for PLD2 (Fig. 5). The major protein detected in this
inhibitory fraction by Coomassie blue staining is approxi-
mately 18 kDa (Fig. 5a), although inhibition by other pro-
teins present at low or undetectable concentrations cannot
be ruled out. The inhibitor is proteinaceous, ruling out
non-protein inhibitors such as oleate. Although the size of
the major protein in the inhibitory fraction is similar to
that of the small GTP-binding proteins, several lines of
evidence suggest that the inhibitor is very unlikely to be
one of them. First, the inhibitor does not stimulate PLD1
in the presence of GTPgS (data not shown). Second, the
inhibitory activity is not GTPgS-dependent. Finally,
unlike all small GTP-binding proteins reported thus far,
the inhibitor is stable to heating at 70°C. The mechanism
of action of the inhibitor is unlikely to be non-specific, as
PLD1 and PLD2 are indistinguishable in terms of cation,
phospholipid and phosphatidylinositol requirements (Fig.
3; and S.M.H. and A.J.M., unpublished observations).
Thus, if the inhibitor were binding or metabolizing PIP2,
PLD1 would also be inhibited. Furthermore, addition of
PIP2 does not overcome the inhibition of PLD2 (data not
shown).
Although the significance of the inhibitor in vivo remains
to be demonstrated, these results nonetheless raise the
possibility that, when expressed at physiological levels in
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Figure 4
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Analysis of PLD2 activity in vivo. (a) The basal activities of PLD1 and
PLD2 were measured by transfecting COS-7 cells with PLD1, PLD2
or control expression plasmids using lipofectamine as previously
described [20]. After allowing 24 h for protein expression and labeling
with [3H]-palmitic acid, butanol was added and the cells were
additionally cultured for the times indicated. The accumulation of [3H]-
phosphatidylbutanol was measured using thin layer chromatography.
(b) To analyse PMA-stimulated PLD activity in vivo, COS-7 cells
transfected as in (a) were additionally stimulated with PMA at the
beginning of the assay period to activate PKC. (c) The relative
increases in PLD1 and PLD2 activities were calculated by subtracting
PMA-stimulated and non-stimulated control values before determining
the ratio of stimulated to unstimulated activity in PLD1- or PLD2-
transfected cells. All experiments were repeated at least three times
with similar results.
the correct cell type, PLD2 is subject to negative regula-
tion in vivo. PLD1 and PLD2 might both play roles in
signal transduction, but might do so through opposing
mechanisms — activation versus derepression. The iden-
tity of a hypothetical effector(s) that could oppose the
action of the inhibitor remains to be determined. With
respect to the tissue source of the inhibitor, PLD2 is
expressed at relatively high levels in the brain (W.C.C.
and M.A.F., unpublished observations), although whether
the inhibitor and PLD2 are expressed in the same cells
and subcellular locations remains an important issue for
future studies.
Two inhibitors of cellular PLD1-like activity have
recently been reported [38,39]. Both inhibitors are rela-
tively large — 300 kDa and 150 kDa. One inhibitor has
been identified as fodrin [38], and the other as synapto-
janin [39]. Fodrin has a pleckstrin homology domain and
additionally inhibits phospholipase C [38]; synaptojanin
hydrolyzes PIP2. Thus, both inhibitors are likely to act by
regulating the availability of PLD cofactors or substrates,
and neither is a good candidate for a PLD2-specific
inhibitor. On the basis of its selectivity and size, the
inhibitor we describe here is clearly different from fodrin
and synaptojanin. 
Subcellular localization of PLD1 and PLD2
PLD activities have been enriched from almost every
region of the cell, including the plasma membrane [15,16],
cytoplasm [15,16], nucleus [40] and ‘endomembranes’
[16], which consist of the Golgi [9], endoplasmic reticulum
(ER) [17] and endosomes. Many of these activities have
been reported to be preferentially activated by one or
more of the various PLD effectors. To begin to determine
which of these activities PLD1 and PLD2 are likely to
account for, we examined the subcellular localization of
influenza-epitope-tagged PLD1 and PLD2 proteins using
microinjection of reporter plasmids into rat embryo fibro-
blasts [41]. 
PLD1 was found exclusively in a peri-nuclear region of
the cell (Fig. 6a). The staining pattern is consistent with
the Golgi, ER, and late endosomes, but not the cytoplasm
or plasma membrane. PLD1 was not observed to be con-
centrated in the nucleus or on the nuclear membrane,
although we cannot rule out the presence of low levels of
PLD1 on the nuclear membrane. A number of recent
reports have suggested that an ARF- [5,7,8] and PKC- [42]
activated PLD plays a role in promoting vesicular budding
and secretion. The localization of PLD1 and its activation
properties suggest that PLD1 may have a major role in the
regulation of peri-nuclear intravesicular membrane traffic.
Ligand–receptor stimulation causes translocation of ARF
to Golgi membranes and subsequent PLD activation [43].
Similar findings have suggested that Rho and PKC also
translocate to the Golgi or ER after agonist stimulation.
Taken together, these findings imply that PLD1’s respon-
siveness to ARF, PKCa and Rho family members may
reflect a coupling of signal transduction and regulated
secretion, rather than a role for PLD1 in constitutive
secretion or in cytoskeletal reorganization at the plasma
membrane [6]. In support of this, serum stimulation of
PLD1-overexpressing cells did not provoke a visible phe-
notype suggestive of cytoskeletal reorganization (Fig. 6b
and data not shown; serum contains factors that stimulate
endogenous PLD1-like activity [1]).
In contrast, PLD2 was predominantly associated with the
plasma membrane in quiescent cells (Fig. 6c). The
periphery of the injected cells was relatively irregular, as
compared to cells injected with a variety of other plasma-
membrane-associated proteins. This can be observed by
comparing the cells injected with PLD2 (Fig. 6c) to ones
injected with activated human ras (Fig. 6e). Activated Ras
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Figure 5
Preferential inhibition of PLD2 by a heat-stable factor from brain.
Extracts were prepared from bovine brain cytosol, heat-denatured at
70°C, and fractionated using column chromatography as described in
Materials and methods. (a) The fraction used in this experiment
contained a major detectable protein of about 18 kDa, as well as minor
quantities of several other, larger proteins. Several preparations of
equivalent fractions have been generated and each exhibits identical
properties. (b) PLD2 activity was measured using a standard
headgroup assay as in Figure 3, in the presence of increasing amounts
of inhibitor. The inhibition of both isoforms of PLD1 (PLD1a and
PLD1b, as described in Materials and methods) was determined in the
presence of ARF because PLD1 does not have significant basal
activity, so the effect of the inhibitor on isolated PLD1 cannot be
assessed. The identity and mechanism of action of the inhibitor are not
known, although the selectivity for PLD2 over PLD1, as well as other
studies (data not shown), rules out the possibility that the inhibitor
degrades, sequesters or otherwise modifies either the
phosphatidylcholine substrate or the polyphosphoinositide cofactors
present in the assays. Identical results for PLD2 were observed in the
presence or absence of either ARF1 and/or GTPgS.
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also accumulated at the plasma membrane, but did not
induce the formation of the ventral cellular projections
observed in the PLD2-overexpressing cells. A small
number of filopodia were also observed in the PLD2-over-
expressing cells. 
Serum stimulation of PLD2-injected cells resulted in an
altered cortical appearance that is most readily apparent as
almost continuous filopodium-like projections from the cell
surface, and accumulation of PLD2 in restricted regions at
the cell edge (Fig. 6d). In addition, redistribution of PLD2
from the plasma membrane to submembranous vesicles was
observed. A similar response was not observed in cells
injected with activated human ras (Fig. 6f); the plasma
membrane remained relatively regular and no redistribution
of Ras was observed. The mechanism by which serum stim-
ulation enhanced the cortical reorganization induced by
PLD2 overexpression is not known. We cannot measure
the degree to which PLD2 was active in the microinjected
cells, and it is possible that the serum stimulation resulted
in heightened activation of PLD2 through effects on PLD2
or cofactors such as PIP2. Alternatively, serum stimulation
might activate other pathways that synergize with PLD2 to
result in the observed cellular response.
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Figure 6
Subcellular localization and overexpression
phenotypes of PLD1 and PLD2. Expression
vectors encoding influenza-epitope-tagged
(a,b) PLD1, (c,d) PLD2 and (e,f) Ras were
microinjected into confluent, serum-starved rat
embryo fibroblasts (REF-52) using
established methods [41]. In some cases
(b,d,f), the cells were additionally stimulated
by serum. Cells were fixed 6–24 h after
microinjection and immunostained using a
monoclonal antibody (12CA5) directed
against the epitope tag. The tagged proteins
were visualized under fluorescence to detect
the Texas Red-labeled secondary antisera. (a)
PLD1 was detected in a peri-nuclear region in
a complex pattern. Non-injected cells present
in the field are not observed under fluorescent
illumination, demonstrating the specificity of
the immunodetection. C6-NBD-ceramide, a
lipid that localizes to the Golgi, overlapped
with a subset of the PLD1 pattern (data not
shown). However, the extended region in
which PLD1 is localized is more consistent
with the ER, and the vesicular structures
observed near the nucleus appear similar to
late endosomes [49]. (b) No change was
observed in cells injected with PLD1 and
stimulated with serum. (c) PLD2 localized
predominantly to the plasma membrane in
serum-starved REF-52 cells. Although the
possibility of a small amount of cytoplasmic
PLD2 can not be excluded, cytoplasmic
localization of a significant amount would
result in decreased staining over the nucleus,
since the nucleus occupies almost the entire
thickness of the cell [41]. Irregular projections
can be observed at the cellular edges. (d) In
serum stimulated cells injected with PLD2,
small irregular projections were present
almost continuously around the periphery of
the cell. At higher power, the projections can
be seen to resemble filopodia (see insert).
PLD2 was also seen to accumulate in
submembranous vesicles near the plasma
membrane. Similar vesicles can be seen to
accumulate over the center of the cell, but are
above the plane of the nucleus. Finally, PLD2
accumulated at restricted regions of the cell
edges (arrowheads); this localization was
variable and was much more prominent in
some cases (data not shown). (e) Human Ras
localized predominantly to the plasma
membrane in serum-starved REF-52 cells. (f)
Ras localization and cell morphology did not
change upon serum stimulation. The insert
shows that the cell edges were not
characterized by frequent filopodia as was
observed for the serum-stimulated cells
producing PLD2 (d). All images were taken at
identical magnifications; at least 20 injected
cells were examined in several experiments for
each condition and representative cells are
shown in each case. Similar results were
obtained using lipofectamine to transfect
PLD1 and PLD2 into COS-7 cells.
Cortical reorganization mediated by actin polymerization
has also been shown to be directed by the small GTP-
binding proteins Rac, Rho and Cdc42, which regulate the
formation of membrane ruffles, lamellipodia and filopodia
[10]. As Rho family members do not activate PLD2 in
vitro, it is not immediately apparent where PLD2 fits into
the scheme of cortical reorganization processes mediated
by the Rho family. On the other hand, preparations of
plasma membrane contain an endogenous PLD activity
that is activated by ARF and Rho [15,16]. It is not clear at
present whether PLD2 is responsible for this reported
activity; it is possible that this activity represents a third,
novel PLD isoform. Alternatively, at physiological concen-
trations and in the endogenous setting (in the presence of
inhibitors or rate-limiting cofactors such as PIP2), PLD2
activity may be directly or indirectly regulated by Rho
family members through an unknown mechanism.
Although the relationship between PLD2 and the path-
ways effected by the small GTP-binding proteins remains
to be clarified, the observations made using microinjection
demonstrate that PLD2 is likely to represent a significant
factor in the morphological response to transduced signals. 
The redistribution of PLD2 into submembranous vesicles
is also intriguing. This is clearly not a passive effect of
serum stimulation, as human Ras, which is also plasma-
membrane localized, does not become redistributed. A
number of recent reports have implicated ARF and
members of the Rho family in receptor-mediated endo-
cytosis. ARF6 is located on the plasma membrane in qui-
escent cells and becomes redistributed in a similar manner
during receptor-mediated endocytosis of transferrin [44].
RhoA, RhoD and Rac1 have also been shown to play a role
in this process [45,46]. Involvement of PLD2 in this
pathway is an attractive hypothesis, since endocytic recy-
cling is functionally analogous in several respects to PLD-
promoted budding from the Golgi complex.
Conclusions
Numerous agonists, ligands, and growth factors have been
reported to activate PLD subsequent to triggering G-
protein-coupled or tyrosine kinase receptors, and a PLD1-
like enzyme has been assumed to account for this activity
[1]. We suggest that PLD2 may account for a significant
part of the reported activity. Key issues to address include
determining whether endogenous PLD2 is activated by
receptor stimulation in vivo, and to what extent this
accounts for the cellular response to external signals.
Despite having different subcellular locations and modes of
regulation, PLD1 and PLD2 may act in concert. Growing
evidence suggests that regulated secretion triggered by
external signals can result in vesicle translocation and the
release of secretagogues in a polarized manner towards the
inducing signal [6,47], which is consistent with there being
distinct and coordinated roles for the two enzymes. We
propose that PLD1 plays a role in the formation and initial
translocation of vesicles from the peri-nuclear region. As
one possibility, PLD2 may play a role in the cytoskeletal
reorganization that results in directed movement of the
vesicles. Alternatively, activation of PLD2 may lead to sub-
sequent activation of PLD1 through the generation of PA
which could then be hydrolyzed to DAG and activate PKC.
Taken together, our findings reveal for the first time a
form of PLD that exhibits an unexpected type of regula-
tion and that can induce changes in cell morphology. In
addition, the results suggest the existence of a novel class
of molecules — PLD2 inhibitors — that are likely to be
involved in the control of signal transduction propagation;
these inhibitors complement the PKCs and GTP-binding
proteins that have previously been reported to activate
PLD1. Previous models for the roles of PLD enzymes will
need to be re-evaluated in the light of these results.
Materials and methods
Molecular isolation of mouse PLD2
Partial mouse PLD2 (mPLD2) cDNAs were obtained from l ZAP II
embryonic day 10.5 mouse embryo and neonatal brain cDNA libraries
(Stratagene, Inc.) as described in the text. The 20 mPLD2 cDNA
clones sequenced (Sequenase Version 2.0, United States Biochemi-
cals; a final sequence was determined from both strands) had
approximately 2.4 kb of coding and 3′ untranslated region (UTR)
sequence but lacked 5′ coding and 5′ UTR sequences. The 5′
sequence was obtained using RACE PCR [30]. The mPLD2 amino-
acid and nucleotide sequences have been deposited in Genbank
under the accession number U87557. There are no unusual features
in the nucleotide sequence. The 3491-nucleotide sequence is likely
to be nearly full length, since the mPLD2 mRNA is approximately 3.5
kb as determined by northern blot analysis (data not shown). The pre-
sumed initiator methionine (nucleotides 138–140) conforms to the
eukaryotic consensus sequence and is the first in-frame methionine in
the 5′ UTR. The coding region is additionally thought to be full length
since an in-frame stop codon is located at nucleotides 58–60 of the
cDNA. The entire 3′ UTR (557 nucleotides) was presumably
obtained, since a recognizable polyadenylation signal sequence is
present starting 19 nucleotides before the 3′ end of the composite
cDNA.
Preparation of affinity-purified PLD2 anti-peptide antibodies 
Peptides corresponding to residues 29–39 and 476–486 of the
sequence of mPLD2 were prepared, conjugated to keyhole limpet
hemocyanin, suspended in saline, and emulsified with Freund’s adju-
vant. Two rabbits were immunized with the peptide corresponding to
residues 29–39, and two additional rabbits were immunized with the
peptide corresponding to residues 476–486, by subcutaneous injec-
tion. After a second immunization, serum was obtained from the
animals and antibody titers determined by enzyme-linked immunosor-
bent assay using the individual peptide antigens as the solid phase.
PLD2-specific antibodies were affinity-purified from serum obtained
from the animals with the highest antibody titers, using affinity chro-
matography in which the immobilized peptide antigens were
employed as the solid phase. The purified antibodies were adjusted
to approximately 1 mg ml–1 and stored as aliquots in buffer containing
10 mM NaPO42–, 20 mM NaCl and 0.1 mM NaN3 at –80°C. These
antibodies recognize PLD2 by western blotting and can immunopre-
cipitate PLD2 under denaturing and non-denaturing conditions. The
peptide antigens were chosen to generate antibodies that can distin-
guish PLD2 from PLD1 (see Fig. 1). The peptide antisera were pre-
pared by Quality Controlled Biochemicals Corporation, Hopkinton,
Massachusetts.
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Preparation of immunoaffinity resin 
A mixture of the two affinity-purified antibodies (1 mg) was adsorbed to
0.5 ml of protein A coupled to Sepharose-CL4B (Sigma) in phosphate-
buffered saline (PBS) for 1 h at room temperature. The resin was
washed with 0.2 M sodium borate, pH 9.0, and the antibodies cova-
lently linked to the immobilized protein A by reaction with 20 mM
dimethylpimelimidate in 0.2 M sodium borate, pH 9.0 for 30 min at
room temperature with constant agitation. The reaction was quenched
by washing the resin in 0.2 M ethanolamine, pH 8, after which the resin
was washed in 100 mM glycine pH 3.0 to remove antibodies that were
not covalently attached. The resin was then washed extensively and
stored in PBS containing 0.1% NaN3.
Expression and purification of activator and PLD proteins 
The expression and purification of recombinant PLD1, ARF, RhoA and
PKCa have been described in detail previously [20,21]. As described
elsewhere, there are two isoforms of PLD1, differing in inclusion
(PLD1a) or exclusion (PLD1b) of a 38 amino-acid exon in the PLD1-
specific loop region [21]. To date, PLD1a and PLD1b have exhibited
identical properties. Both PLD1a and PLD1b were used for the experi-
ments described in this paper. 
The mPLD2 cDNA was inserted into the unique SmaI and Not I sites of
the pVL1392 transfer vector (Invitrogen Inc.), and recombinant bac-
uloviruses harboring the cDNA were generated, selected and propa-
gated using standard methods [20,21,48]. In brief, monolayers of sf9
insect cells were transfected with a mixture of the PLD2 transfer vector
and linearized wild-type baculovirus DNA. Recombinant baculoviruses
were plaque-purified from media removed from these transfected cells.
The pure viruses were amplified by infection of suspension cultures of
sf9 cells and the high-titer virus stocks obtained were stored at 4°C. 
To express PLD2, monolayers of exponentially growing sf9 cells
(3 × 107 cells per 225 cm2 flask; generally two flasks of cells for each
purification) were infected with recombinant baculoviruses at a multi-
plicity of 10 for 1 h with gentle rocking. After the 1 h infection, the virus-
containing medium was removed and replaced with fresh
supplemented Grace’s medium. The infected cells were grown for
48 h, the media removed, and the cells washed once with ice-cold
PBS. The cells were lysed on ice by addition of 5 ml per 225 cm2 flask
of ice-cold lysis buffer containing 150 mM NaCl, 50 mM Tris, pH 8.0,
1% Nonidet P-40, 1 mM EGTA, 0.1 mM benzamidine, 0.1 mM PMSF,
10 mg ml–1 pepstatin A, and 10 mg ml–1 leupeptin. After 30 min on ice,
the cells were scraped up and the suspension centrifuged at 50 000 g
for 30 min at 4°C. The supernatant obtained (10 ml, containing approxi-
mately 45 mg protein) was mixed with 0.5 ml anti-PLD2 immunoaffinity
resin (see above) and kept at 4°C with constant agitation on a rotary
platform for 1 h. The resin was then sedimented by gentle centrifuga-
tion (500 g × 3 min) and the supernatant containing unbound proteins
removed, following which the resin was washed three times with
25 volumes of lysis buffer. After the final wash, the resin was resus-
pended in 5 ml of lysis buffer and transferred to a 10 ml BioRad dis-
posable chromatography column. The resin was then washed with
10 ml 10 mM phosphate buffer, pH 6.8, containing 1% b-D-octylgluco-
side (b-DOG). Bound protein was eluted using 100 mM glycine,
pH 3.0, containing 1% b-DOG. Application of three 0.5 ml aliquots of
elution buffer sufficed to elute all of the PLD2. The eluant was collected
as separate 0.5 ml fractions on ice into tubes containing 0.075 ml 1 M
phosphate buffer, pH 8.0. Fractions recovered from the immuno-
purification were tested for activity and examined by SDS–PAGE and
western blotting using standard procedures, as shown in Figure 2. By
Coomassie blue staining, silver staining, and western blot analysis,
PLD2 was the only detectable protein present after purification.
Although the presence of trace amounts of contaminating proteins
cannot be rigorously ruled out, no other protein was present in anything
approaching stoichiometric quantities. The immunopurification proce-
dure was also carried out for sf9 cells expressing an unrelated phos-
pholipase C protein (details in [21]). No visible protein was recovered
and no fraction exhibited PLD activity in the standard in vitro assay.
Approximately 10 mg PLD2 was recovered from two 225 cm2 flasks,
which corresponds to a 20–30% yield of the PLD2 activity present in
the starting sf9 cell detergent extract (PLD activity in the detergent
extracts was determined after detergent removal by gel-filtration chro-
matography). Purified PLD2 had a specific activity of approximately
9 mmol min–1 mg–1 under our standard assay conditions. Although the
most effective extraction of the protein requires detergent treatment,
approximately 50% of the membrane-bound PLD2 activity can be
extracted with 0.5 M NaCl. However, in the absence of detergents,
enzyme activity is less stable. The purified protein is kept at 4°C in
buffer containing 1% b-DOG and is stable for several days. 
PLD assays
The basic PLD in vitro assay was performed as described previously
using headgroup-labeled phosphatidylcholine [20,21,32]. Approxi-
mately 10 ng PLD2 was used for each assay sample. Purified small
GTP-binding proteins and PKCa were included in some of the experi-
ments, as described previously [21]. The small GTP-binding proteins
were preloaded with GTPgS after EDTA-mediated stripping as
described previously [21]. PKCa was activated in the assay tube by
the addition of PMA to a final concentration of 100 nM. ATP was not
present in the assay tubes to which PKCa was added. In general,
reagents were mixed on ice and reactions initiated by transfer to a
37°C water bath. Choline release varied linearly over time and in pro-
portion to the amount of protein added. 
PLD assays in vivo were performed exactly as described elsewhere
[33]. For transient transfection experiments, an influenza-epitope tag
was appended to the amino terminus of PLD2 and expression of the
hybrid RNA was driven by the CMV promoter (the same vector was
used previously to achieve transient transfection of PLD1; see [20]).
Using lipofectamine, a typical transfection efficiency of 5–10% of the
subconfluent COS-7 cells present in a dish was observed. Recombi-
nant protein was visualized by either immunofluorescence or western
blotting using the commercially available monoclonal antibody 12CA5
(Boerhinger Mannheim). After transfection of a 35 mm plate of subcon-
fluent COS-7 cells, PLD1 and PLD2 could be detected easily by
western blotting of 10% of the transfected cells. The relative amounts
of protein expressed were difficult to quantitate because PLD1 has a
tendency to become trapped at the interface between the stacking and
resolving gels to a variable extent [21]. No obvious differences in spe-
cific activities or in responses to activators were observed for the native
PLDs (1 and 2) produced using baculovirus compared to the epitope-
tagged PLDs produced in COS-7 cells.
Enrichment of the PLD2-specific inhibitor
In brief, bovine brain tissue was homogenized in fresh ice-cold TED
(20 mM Tris, pH 8.0, 1 mM EDTA, 1 mM DTT) buffer containing pro-
tease inhibitors. The homogenate was spun for 45 min at 20 000 g to
pellet most of the membrane fraction. The supernatant was harvested
and spun further for 60 min at 100 000 g to pellet the remaining partic-
ulate material. The clarified supernatant was then incubated at 70°C
for 45 min. Denatured proteins were removed by centrifugation for
30 min at 100 000 g, and the supernatant concentrated 25-fold by
pressure filtration. The concentrate was applied to a 500 ml Sephacryl
S-300 HR gel-filtration column equilibrated with TED buffer. Fractions
(6 ml) were collected after the void volume (150 ml) had passed. Two
peaks of inhibitory activity were observed, the second of which (frac-
tions 27–38) exhibited a PLD2-specific activity. These fractions were
then applied to a Source 15Q (Pharmacia) column equilibrated with
TED buffer and eluted with a 100 ml gradient of 0–400 mM NaCl, col-
lecting 2 ml fractions. Three peaks of inhibitory activity were detected,
the third of which (fractions 28–35) contained the PLD2-specific
inhibitory activity. These fractions were concentrated by pressure filtra-
tion, transferred into HED buffer (20 mM HEPES, pH 7.4, 1 mM EDTA,
1 mM DTT), and applied to a 5 ml heparin–Sepharose (Pharmacia)
column. The column was eluted with a 50 ml gradient of 0–500 mM
NaCl, collecting 1 ml fractions. Fractions 9–20 contained an activity
which strongly and specifically inhibited PLD2. Fractions were pooled,
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concentrated as above, and stored at –80°C. The preparation con-
tained a protein of approximately 18 kDa as assessed by SDS–PAGE,
with a purity of > 95% as assessed by Coomassie staining. 
Microinjection of PLD expression plasmids
Microinjections were carried out as described previously [41] using
influenza-epitope-tagged PLD proteins expressed under the control of
a CMV promoter. Cells were fixed 6–24 h after microinjection and ana-
lyzed immunohistochemically to detect the expressed proteins. A com-
mercial monoclonal antibody, 12CA5 (Boerhinger Mannheim), was
used to detect the influenza (HA) tag. HA epitope tagging is widely
used to determine protein localization and the epitope is not thought to
influence subcellular localization. Nonetheless, until confirmed by
detection of the endogenous proteins, it remains a formal possibility
that the epitope or overexpression itself may influence the subcellular
localization observed.
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